Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View

doi 10.36502/2020/droa.6156
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Asploro Open Access Publications

Related search

Erratum To: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Cardiology and Therapy
2016English

Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2018English

Exploring Novel Pharmacotherapeutic Applications and Repurposing Potential of Sodium Glucose CoTransporter 2 (SGLT2) Inhibitors

Clinical and Experimental Pharmacology and Physiology
PhysiologyPharmacology
2018English

Differential Cardiovascular Profiles of Sodium-Glucose Cotransporter 2 Inhibitors: Critical Evaluation of Empagliflozin

Therapeutics and Clinical Risk Management
2017English

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2015English

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

Journal of Clinical Medicine Research
2017English

Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Effects of Sodium Glucose Cotransporter Type 2 Inhibitors on Heart Failure

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy